Replimune stock.
During the last session, Replimune Group Inc (NASDAQ:REPL)’s traded shares were 0.83 million, with the beta value of the company hitting 1.46. At the end of the trading day, the stock’s price was $11.71, reflecting an intraday gain of 4.74% or $0.53. The 52-week high for the REPL share is $29.52, that puts it down -152.09 from that peak ...
Replimune | Stock Quote & Chart Investors & Media Overview Events and Presentations Press Releases Corporate Governance Financials & Filings Stock Information Publications Email Alerts Investor Contact Select Page Stock Quote & Chart Stock Quote & Chart Historical Price Analyst Coverage Change Volume Today's Open Previous Close Today's HighReplimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death …Nov 8, 2023 · WOBURN, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced updated data from a cohort of metastatic uveal melanoma patients enrolled in the open-label, multicenter, Phase 1 study of RP2 as a single agent and in combination with nivolumab. Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip ...Replimune stock traded as low as $27.66 on August 26th, marking a near round trip from before its SITC presentation. There is plenty of competition in the oncolytic immunonocology space, but with ...
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies.
If you want to keep up to date on the stock market you have a device in your pocket that makes that possible. Your phone can track everything finance-related and help keep you up to date on the world markets.
Replimune Group Inc [REPL] stock prices are up 4.74% to $11.71 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The REPL shares have gain 12.70% over the last week, with a monthly amount drifted -18.05%, and not seem to be holding up well overReplimune Group Inc REPL Morningstar Rating Stock XNAS Rating as of Nov 24, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns …Replimune’s tumor-directed oncolytic immunotherapies have the potential to redefine the cancer treatment paradigm. Replimune’s approach brings together multiple mechanisms of action to destroy the tumor, ignite an anti-cancer response, and generate long-lived immune activity. The ultimate aim is to improve outcomes for patients with cancer.Replimune Group - REPL - Stock Price Today - Zacks Replimune Group (REPL) (Delayed Data from NSDQ) $10.40 USD +0.08 (0.78%) Updated Nov 17, 2023 …
Replimune is pioneering a new generation of cancer treatments called oncolytic immunotherapies. These cleverly designed therapeutics combine multiple mechanisms of action, enhancing the ability of viruses to replicate in and kill cancer cells, generating a powerful patient-specific, systemic immune response. Oncolytic immunotherapy enhances the ...
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added ...
Feb 24, 2023 · Replimune Group, Inc. (REPL) has been beaten down lately with too much selling pressure. While the stock has lost 14.6% over the past four weeks, there is light at the end of the tunnel as it is ... Complete Replimune Group Inc. stock information by Barron's. View real-time REPL stock price and news, along with industry-best analysis.Feb 27, 2023 · Replimune ends selloff after FDA response to mid-stage cancer trial. Following four straight sessions of losses, oncology-focused biotech Replimune Group ( NASDAQ: REPL) added ~7% on Monday after ... May 18, 2023 · Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death and the ... Finally, Rhumbline Advisers raised its position in Replimune Group by 1.3% in the third quarter. Rhumbline Advisers now owns 70,544 shares of the company’s stock worth $1,207,000 after acquiring an additional 939 shares during the period. Institutional investors own 92.53% of the company’s stock. Replimune Group Company Profile (Get …In addition, Replimune has granted the underwriters a 30-day option to purchase up to an additional 1,436,172 shares of its common stock from Replimune at the public offering price, less the ...WOBURN, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today announced a clinical development update for CERPASS, its registration-directed global randomized Phase 2 clinical trial of RP1 in combination with …
The Replimune Group Inc. stock price fell by -1.82% on the last day (Wednesday, 29th Nov 2023) from $11.53 to $11.32.During the last trading day the stock fluctuated 6.13% from a day low at $11.26 to a day high of $11.95.The price has been going up and down for this period, and there has been a 0.89% gain for the last 2 weeks.According to Accountingbase.com, common stock is neither an asset nor a liability; it is considered equity. Equity is basically considered to mathematically be the difference between the total assets and total liabilities of a company.BMO Capital Markets raised the price target on Replimune Group Inc (NASDAQ: REPL) to $40 from $30 on a bullish view into upcoming data readouts for lead asset RP1 in melanoma and cutaneous ...Find the latest Replimune Group, Inc. (REPL) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies.
Dec 1, 2023 · Replimune to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. WOBURN, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic imm... 2 days ago · What is the target price for Replimune Group (REPL) stock? A The latest price target for Replimune Group ( NASDAQ : REPL ) was reported by HC Wainwright & Co. on Monday, November 13, 2023 .
Replimune Group, Inc. Common stock $ per share . Replimune Group, Inc. is offering 5,000,000 shares of common stock. Our common stock is listed on the Nasdaq Global Select Market, or Nasdaq, under the symbol "REPL." On November 11, 2019, the last reported sale price of our common stock on Nasdaq was $17.21 per share. ...REPL News. This page features the latest news about the Replimune stock. Replimune earnings missed by $0.09, revenue was in line with estimates. By Investing.com. • Nov 07, 2023. Replimune ...Finally, Rhumbline Advisers raised its position in Replimune Group by 1.3% in the third quarter. Rhumbline Advisers now owns 70,544 shares of the company’s …S-3 1 tm2027068-1_s3.htm FORM S-3 ...Replimune | Stock Quote & Chart Investors & Media Overview Events and Presentations Press Releases Corporate Governance Financials & Filings Stock Information Publications Email Alerts Investor Contact Select Page Stock Quote & Chart Stock Quote & Chart Historical Price Analyst Coverage Change Volume Today's Open Previous Close Today's High Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.Igniting a systemic immune response to cancer. Replimune’s mission is to revolutionize cancer treatment with therapies designed to activate a powerful and …Contact Email: [email protected]. Contact Phone Number: +1 (781) 222 9570. Replimune’s investigational products and their uses are investigational, have not been proven to be safe and have not been approved by the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA) or any other regulatory authority.
When it comes to purchasing a new vehicle, finding the perfect car that meets all your requirements can be a daunting task. If you have your heart set on a Genesis GV70, you’ll want to ensure that you find the best one available in stock.
Novartis AG. -0.52%. CHF176.38B. REPL | Complete Replimune Group Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
Replimune Group's results for treatment of patients with cutaneous squamous cell carcinoma are expected in Q4 2023. Click here to read our take on REPL stock.Billionaires Julian and Felix Baker have been some of the best bio-stock pickers over the past 20 years. ... (CERS-3.09%), and Replimune Group (REPL 0.31%) in the most recent quarter. All three of ...The shares of the biotechnology company that develops oncolytic immune-gene therapies to treat cancer jumped 46% in Wednesday trading, accelerating twelve months gains to 196%. Replimune stock price has been receiving support from the successful results of the Phase 1 clinical trial of RP1 and RP2 in patients with solid tumors.Replimune story: Exercise or conversion by Pamela Esposito of 25800 shares of Replimune subject to Rule 16b 3 and other headlines for Replimune GroupIf you are looking for stocks with good return, Replimune Group Inc stock can be a bad, high-risk 1-year investment option. Replimune Group Inc real time quote is equal to 10.390 USD at 2023-11-25, but your current investment may be devalued in the future.WOBURN, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing a range of product candidates derived from its oncolytic immuno-gene therapy platform, today announced the appointment of Christy Oliger to the Company’s Board of Directors effective December 1, 2021. “We are delighted to …Replimune Group's results for treatment of patients with cutaneous squamous cell carcinoma are expected in Q4 2023. Click here to read our take on REPL stock.REPL Replimune Group Inc Form 8-K - Current report false 0001737953 0001737953 2023-11-07 2023-11-07 iso4217:USD xbrli:shares ...WOBURN, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced updated data from a cohort of metastatic uveal melanoma patients enrolled in the open-label, multicenter, Phase 1 study of RP2 as a single agent and in combination with nivolumab.S-3 1 tm2027068-1_s3.htm FORM S-3 ...Today's High Today's Low 52 Week High 52 Week Low FL Technical Analysis Tools & Settings Open High Low Close Volume Volume remove 1DY | 5DY | | 3M | | YTD | | | | Max |29 Jun 2020 ... The offering consisted of shares of Replimune's common stock and pre‑funded warrants to acquire shares of its common stock. The shares were ...
Find real-time REPL - Replimune Group Inc stock quotes, company profile, news and forecasts from CNN Business.Insider Sell: Pamela Esposito Sells 5,658 Shares of Replimune Group Inc. On September 12, 2023, Pamela Esposito, the Chief Business Officer of Replimune Group Inc (NASDAQ:REPL), sold 5,658 shares ...Oncolytic virus experts at Replimune reload with $200M loan as biotech collects clinical data ... cal plans from raking in the cash — either through stock offerings or ...Nov 29, 2023 · Replimune Readies $100 Million U.S. IPO. Find the latest Replimune Group, Inc. (REPL) stock analysis from Seeking Alpha’s top analysts: exclusive research and insights from bulls and bears. Instagram:https://instagram. sdc stovkwhy is stock down todayvanguard after hours tradingnasdaq rxrx Historical daily share price chart and data for Replimune since 2018 adjusted for splits and dividends. The latest closing stock price for Replimune as of November 24, 2023 is 10.39.. The all-time high Replimune stock closing price was 52.65 on December 01, 2020.; The Replimune 52-week high stock price is 29.52, which is 184.1% above the current share …Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip ... price of oil today marketwatchkennedy silver dollar value 1964 Rocket Pharmaceuticals, Inc. 22.82. +0.57. +2.54%. In this article, we will take a look at the 12 stocks with biggest upside potential according to analysts. To skip our analysis of recent market ... t stock dividends At Replimune, we are developing an emerging class of cancer treatments called oncolytic immunotherapies. Oncolytic immunotherapy has the potential to treat patients with a variety of tumor types and improve on existing immunotherapies. Our goal is to revolutionize cancer treatment by making personalized therapy a practical reality for all ...37 Salaries (for 31 job titles) • Updated Oct 29, 2023. How much do Replimune employees make? Glassdoor provides our best prediction for total pay in today's job market, along with other types of pay like cash bonuses, stock bonuses, profit sharing, sales commissions, and tips. Our model gets smarter over time as more people …